Navigation Links
Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
Date:10/24/2013

SAN DIEGO, Oct. 24, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced the pricing of an underwritten public offering of 4,150,000 shares of common stock at an offering price of $7.25 per share.  The shares will begin trading on The NASDAQ Capital Market on October 25, 2013 under the symbol "SRNE." The gross proceeds to Sorrento from this offering are expected to be approximately $30 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on or about October 30, 2013, subject to customary closing conditions. Sorrento has granted the underwriters a 45-day option to purchase up to an additional 622,500 shares of common stock to cover over-allotments, if any.

Sorrento intends to use the net proceeds received from the offering to fund its research and development activities, including its registrational clinical trial of Cynviloq™, for working capital, other general corporate purposes, and possibly acquisitions of other companies, products or technologies.

In connection with its listing on The NASDAQ Capital Market, Sorrento's common stock will cease trading on the OTC QB.   

Aegis Capital Corp. is acting as the sole book-running manager for this offering.

CRT Capital is acting as co-manager for this offering. 

A shelf registration statement and accompanying base prospectus on Form S-3 relating to the shares was filed with the Securities and Exchange Commission and is effective.  A preliminary prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC's web site at http://www.sec.gov. Copies of the final prospectus supplement, when available, may be obtained from the SEC's web site or the offices of Aegis C
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
2. Sorrento Therapeutics Completes IgDraSol Merger
3. Sorrento Therapeutics to Present at Two Healthcare Conferences
4. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
5. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
6. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
7. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
8. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
9. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
10. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
11. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014  Today DePuy Synthes Companies of Johnson ... systems featuring its proprietary variable angle locking technology. ... to match patient anatomy and fracture pattern and ... systems are being introduced in conjunction with the ... the International Federation of Foot & Ankle Societies ...
(Date:9/19/2014)... VIEW, Calif. , Sept. 19, 2014 Today, ... in capital from Xiaomi Ventures, Ltd. for its first ... used to continue expanding iHealth,s global reach, accelerate growth ... resources.  As part of the investment, Xiaomi Ventures will ... the areas of cloud infrastructure and ecommerce. ...
(Date:9/19/2014)...  The board of directors of AbbVie Inc. (NYSE: ... of $0.42 per share.  The cash ... record at the close of business on Oct. 15, ... research-based biopharmaceutical company formed in 2013 following separation from ... dedicated people and unique approach to innovation to develop ...
Breaking Medicine Technology:DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3iHealth Raises $25 Million to Fuel Growth and Global Market Share 2
... Cargill today announced encouraging preliminary results from its ... head of beef cattle.  Initial results are based upon ... company,s Fort Morgan, Colo., beef processing facility where vaccinated ... Addressing the food and feed safety ...
... Nov. 15, 2010 Breathe Technologies, manufacturer of devices ... has appointed Lawrence A. Mastrovich as the new President ... us a phenomenal wealth of experience and strategic guidance," ... visible and instrumental role in building value within the ...
Cached Medicine Technology:Cargill Encouraged by Preliminary Results From Beef Cattle Vaccine Trial 2Cargill Encouraged by Preliminary Results From Beef Cattle Vaccine Trial 3Breathe Technologies Appoints New CEO 2
(Date:9/21/2014)... of cancer patients who smoke, those using e-cigarettes (in ... equally or less likely to have quit smoking traditional ... , a peer-reviewed journal of the American Cancer Society, ... e-cigarettes for helping cancer patients give up smoking. , ... patients who smoke should be advised to quit. But ...
(Date:9/21/2014)... Texas (PRWEB) September 22, 2014 ... originally launched in 1997, and is used prophylactically ... and adults. Its active ingredient, budesonide, is an ... corticosteroid receptor. AstraZeneca’s Pulmicort franchise includes the Pulmicort ... than six years of age, Pulmicort Respules for ...
(Date:9/21/2014)... More than a quarter of house fires are started ... two ways. The first type of dryer fire occurs when ... of dryer fire occurs when lint builds up in the dryer ... to malfunctioning electrical systems so if it doesn’t appear to be ... are some ways that you can prevent dryer fires. , Clean ...
(Date:9/21/2014)... 21, 2014 Burnaby Physiotherapists at Absolute ... clients in order to help them with preventative care. ... the clinic that will help clients understand their problem ... take active participation in the healing process. With higher ... will be able to facilitate the therapy that is ...
(Date:9/21/2014)... 21, 2014 Waldorf Risk Solutions, ... Portal designed for Diocesan risks. The portal features ... support effective risk management and loss control client ... coinciding with Waldorf’s exhibition at the Diocesan Fiscal ... applications were developed in collaboration with three Risk ...
Breaking Medicine News(10 mins):Health News:E-cigarettes unhelpful in smoking cessation among cancer patients 2Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Restoration Local Offers Tips to Avoid Dryer Fires 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 3Health News:Burnaby Physiotherapists Now Provide Educational Information for Preventative Care 2Health News:Waldorf Risk Solutions Releases New Risk Management Portal 2
... , , CHICAGO, July 14 ... people of Chicago, SAVE THE PATIENT, a not-for-profit patient-focused organization, ... Chicago Access Network Television (CAN-TV) airing Monday, July 20, 2009 ... , Monday,s program will feature a ...
... , , , ... leading developer of video analytics-enabled products, announced today that ... Cernium,s server-based enterprise video analytics software solution. Perceptrak will ... the Baltimore, Maryland medical center campus. , ...
... , , OAKLAND, Calif., July 14 ... Health Manager, Kaiser Permanente,s personal health record, are overwhelmingly satisfied with ... from the recent Kaiser Permanente survey examining Web site usage and ... Congress, 5th Annual Leadership Summit on Medicare in Washington, D.C. , ...
... prevent injuries, experts say , TUESDAY, July 14 (HealthDay News) ... and your mental health. , But running can be tough ... shin splints, stress fractures, pulled muscles, ankle sprains, plantar fasciitis ... back. , To prevent injuries, make sure you take precautions, ...
... better screening: study , TUESDAY, July 14 (HealthDay News) ... cancers noted in the United States since 1980, and scientists ... A new study finds that thyroid tumors of all sizes ... more aggressive screening would be expected to detect. , ...
... , , SAN DIEGO, ... today announced that OraVerse(R), the company,s premier dental pharmaceutical product, has ... of its Top 100 Products for 2009. The full results ... , , OraVerse is the first ...
Cached Medicine News:Health News:Women's Health - An Intimate Discussion 2Health News:Johns Hopkins Medical Institutions Deploys Perceptrak(R) by Cernium 2Health News:Kaiser Permanente Survey Shows Seniors Embrace Internet to Manage Their Health 2Health News:Kaiser Permanente Survey Shows Seniors Embrace Internet to Manage Their Health 3Health News:Get the Most Out of Your Run 2Health News:Get the Most Out of Your Run 3Health News:Increase in Thyroid Cancer Puzzles Experts 2Health News:OraVerse (R) Selected by Dentistry Today Magazine as One of the Top 100 Products of 2009 2Health News:OraVerse (R) Selected by Dentistry Today Magazine as One of the Top 100 Products of 2009 3
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
... that quantitatively measure two important cardiac risk ... serum or plasma homocysteine level is increasingly ... factor for cardiovascular disease. And numerous studies ... levels of Lp(a) with increased risk of ...
... ELISA products for autoimmune testing feature single-well ... well as specific reflex tests including dsDNA, ... SS-A (Ro), SS-B (La), Scl-70 and Jo-1. ... a full line of products for Cardiolipins ...
Anti-Skin Antibody (ASA) Test Kit: Pemphigus and Bullous Pemphigoid...
Medicine Products: